Lytix Biopharma, is pleased to announce that it will host a Capital Markets Day
for investors, analysts and media on Tuesday, November 22, 2022.

The topic will be the versatility of our technology platform and further outlook
for the clinical program, and the event will be open for physical attendance in
Oslo, Norway, and as a live webcast. It is scheduled to start at 14.30 CET, and
is expected to last approximately two hours, including Q&A.

Speakers will be Niels Junker, Chief Physician at Herlev Hospital and
investigator at the ATLAS-IT-04 proof-of-concept study, Aurélien Marabelle,
Professor of Clinical Immunology, Université Paris Saclay and an internationally
recognized expert on intratumoral cancer treatment, CBO Stephen Worsley and CEO
Øystein Rekdal of Lytix.

The management team will be available at the event.

Further details of the agenda and registration details will follow.